ArticleScience (New York, N.Y.)2018
Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin.
Article in Science (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed.
- A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study.Nature communications · 2026Trial
- Article
- Time-Multiplexed Organic Electrochemical Transistor for Saliva-Based Rapid Detection of Viral Proteins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- A C-type single-domain antibody with protective efficacy against H1N1 via respiratory administration.Virologica Sinica · 2026Article
- Article
- DNA Nanostructure-Templated Multivalency Enables Broad-Spectrum Virus Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A yeast synthetic biotic platform for delivery of therapeutic nanobodies to ameliorate gastrointestinal inflammation.Disease models & mechanisms · 2026Article
- Demonstration ofJournal of virology · 2026Article
- Protection against lethal canine distemper virus infection by a dual epitope-targeting synthetic antibody.Nature communications · 2026Article
- VNpj viruses · 2025Article
- Review
- SAAINT-DB: a comprehensive structural antibody database for antibody modeling and design.Acta pharmacologica Sinica · 2025Article
- Development of Nanobody-Expressing Nanosomes for Neutralization of Influenza Virus.Journal of microbiology and biotechnology · 2025Article
- Targeting Claudin18.2 for cancer theranostics: From molecular imaging to precision therapy.iScience · 2025Review
- High-throughput synthesis and specificity characterization of natively paired influenza hemagglutinin antibodies with oPoolScience translational medicine · 2025Article
- Cross-species tropism of AAV.CPP.16 in the respiratory tract and its gene therapies against pulmonary fibrosis and viral infection.Cell reports. Medicine · 2025Article
- Nanobodies: From Discovery to AI-Driven Design.Biology · 2025Review
- Small but Mighty: Nanobodies in the Fight Against Infectious Diseases.Biomolecules · 2025Review
- A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors.
Funding
Abstract
Broadly neutralizing antibodies against highly variable pathogens have stimulated the design of vaccines and therapeutics. We report the use of diverse camelid single-domain antibodies to influenza virus hemagglutinin to generate multidomain antibodies with impressive breadth and potency. Multidomain antibody MD3606 protects mice against influenza A and B infection when administered intravenously or expressed locally from a recombinant adeno-associated virus vector. Crystal and single-particle electron microscopy structures of these antibodies with hemagglutinins from influenza A and B viruses reveal binding to highly conserved epitopes. Collectively, our findings demonstrate that multidomain antibodies targeting multiple epitopes exhibit enhanced virus cross-reactivity and potency. In combination with adeno-associated virus-mediated gene delivery, they may provide an effective strategy to prevent infection with influenza virus and other highly variable pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.